Additionally, as shown in Figure 8, we found that compound 2 increased the expression of Pparα, a gene involved in fatty acid oxidation and Pparγ, in comparison to untreated mice, a validated target in NAFLD/NASH management. The gene discussed is PPARG; the disease is metabolic dysfunction-associated steatotic liver disease.